SOX17 is a SRY-box transcription factor that functions as a key developmental regulator binding DNA sequences containing AACAAT or AACAAAG motifs 1. During embryonic development, SOX17 is essential for definitive gut endoderm formation, cardiac tube looping, and vascular development 2. It regulates fetal hematopoietic stem cell generation and germ cell specification 3, while antagonizing canonical Wnt signaling through CTNNB1 degradation. Beyond developmental roles, SOX17 plays a critical function in early colorectal cancer progression by suppressing interferon-γ responses and MHC-I expression, enabling immune evasion of pre-malignant adenomas 4. Clinically, SOX17 variants contribute significantly to pulmonary arterial hypertension (PAH) pathogenesis. Genome-wide association studies identified SOX17 locus variants (rs10103692, rs13266183) strongly associated with PAH susceptibility, with functional evidence showing risk variants alter endothelial enhancer activity 5. Rare deleterious SOX17 mutations account for approximately 3.2% of PAH cases associated with congenital heart disease and 0.7% of idiopathic PAH 6. These findings establish SOX17 as both a developmental master regulator and a disease-critical transcription factor with implications for cancer immunology and cardiovascular pathology.